Du är här

2014-05-23

Ad hoc: Biofrontera AG: License Agreement for Ameluz® in Switzerland and Liechtenstein with Louis Widmer SA

Biofrontera AG / Keyword(s): Misc. matters /Ad hoc: Biofrontera AG: License
Agreement for Ameluz® in Switzerland and Liechtenstein with Louis Widmer SA.
Ad hoc announcement according to § 15 WpHG. Processed and transmitted by
NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the
content of this announcement.
Leverkusen, 23 May 2014 - Biofrontera Pharma GmbH, a fully-owned subsidiary of
Biofrontera AG, has today signed an exclusive agreement with Louis Widmer SA,
Schlieren, Switzerland, for the marketing of Ameluz®and BF-RhodoLED®in
Switzerland and Liechtenstein. In December 2011 Ameluz®received the
centralized European approval as prescription medicament for the first-line
treatment of mild and moderate actinic keratosis. Actinic keratosis is a
sun-induced, superficial skin cancer which may develop into squamous cell
carcinoma. Ameluz®is used together with the red-light source BF-RhodoLED®in
photodynamic therapy (PDT), by which tumour cells in the skin are selectively
killed. The treatment results in highest cure rates accompanied by a strong
skin rejuvenation effect.

Louis Widmer is a pharmaceutical company well established in Switzerland and
is dedicated to, among other things, the commercialization of innovative
ethical pharmaceuticals and medical devices.

Louis Widmer will, with Biofrontera's assistance, take responsibility for
national Swiss approval of Ameluz®and BF-RhodoLED®. The company will purchase
Ameluz®from Biofrontera at 50% of Louis Widmer's net selling price and take
over all local costs and responsibilities during the marketing phase. For
providing the license Biofrontera will obtain a downpayment totalling €
100,000 upon achievement of milestones related to national approval and
reimbursement.

Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen
ISIN: DE0006046113
WKN: 604611

Contact:
Biofrontera AG
Tel.: +49 (0214) 87 63 2 0, Fax.: +49 (0214) 87 63 290
E-mail:press@biofrontera.com

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Biofrontera AG via Globenewswire

HUG#1788247

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.